Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Operating Leases (2019 - 2025)

Abvc Biopharma (ABVC) has disclosed Operating Leases for 7 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 575.97% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Dec 2025, up 575.97%, and an annual FY2025 reading of $1.6 million, up 575.97% over the prior year.
  • Operating Leases was $1.6 million for Q4 2025 at Abvc Biopharma, up from $164072.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.6 million in Q4 2025 and bottomed at $142201.0 in Q3 2024.
  • Average Operating Leases over 5 years is $641161.6, with a median of $507229.0 recorded in 2023.
  • The sharpest move saw Operating Leases soared 651.04% in 2021, then plummeted 74.77% in 2022.
  • Year by year, Operating Leases stood at $1.1 million in 2021, then decreased by 29.6% to $791827.0 in 2022, then plummeted by 48.54% to $407457.0 in 2023, then crashed by 41.88% to $236807.0 in 2024, then soared by 575.97% to $1.6 million in 2025.
  • Business Quant data shows Operating Leases for ABVC at $1.6 million in Q4 2025, $164072.0 in Q3 2025, and $177133.0 in Q2 2025.